A new PET tracer specific for vascular endothelial growth factor receptor 2

Wang, Hui; Cai, Weibo; Chen, Kai; Li, Zibo; Kashefi, Amir; He, Lina; Chen, Xiaoyuan

doi:10.1007/s00259-007-0524-0

Cited by 103 publications

(93 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemical modifications, such as PEG, have been shown to reduce non-specific liver uptake (Chen et al 2004b). In addition, modifying the chemical properties of peptide sequences (Ekblad et al 2008), or increasing specificity by altering the binding affinity to other target family members (Wang et al 2007a) have been used to improve the tissue biodistibution of in vivo molecular imaging agents.…”

Section: The Process Of Developing Phage-derived In Vivo Molecular Immentioning

confidence: 99%

Phage display and molecular imaging: expanding fields of vision in living subjects

Cochran

2010

Biotechnology and Genetic Engineering Reviews

View full text Add to dashboard Cite

In vivo molecular imaging enables non-invasive visualization of biological processes within living subjects, and holds great promise for diagnosis and monitoring of disease. The ability to create new agents that bind to molecular targets and deliver imaging probes to desired locations in the body is critically important to further advance this field. To address this need, phage display, an established technology for the discovery and development of novel binding agents, is increasingly becoming a key component of many molecular imaging research programs. This review discusses the expanding role played by phage display in the field of molecular imaging with a focus on in vivo applications. Furthermore, new methodological advances in phage display that can be directly applied to the discovery and development of molecular imaging agents are described. Various phage library selection strategies are summarized and compared, including selections against purified target, intact cells, and ex vivo tissue, plus in vivo homing strategies. An outline of the process for converting polypeptides obtained from phage display library selections into successful in vivo imaging agents is provided, including strategies to optimize in vivo performance. Additionally, the use To whom correspondence may be addressed (cochran1@stanford.edu) Abbreviations: scFv, single chain variable fragment; Fab, fragment antigen binding; ELISA, Enzyme-Linked Immunosorbent Assay; NEB, New England Biolabs; PET, positron emission tomography; SPECT, single photon emission computed tomography; NIR, near infrared; PEG, polyethylene glycol; SPARC, secreted protein acidic and rich in cysteine; VCAM-1, vascular cell adhesion molecule; MRI, magnetic resonance imaging; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; IC 50 , half maximal inhibitory concentration; CT, computed tomography; K D , equilibrium dissociation constant; EGFR, epidermal growth factor receptor; EGFR-ECD, EGFR extracellular domain; Aβ 42 , amyloid-beta; MMP, matrix metalloprotease; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor; IL-11, Interleukin-11; IL-11αR, Interleukin-11 α-receptor. 58F.V. CoChran and J.r. CoChran of phage particles as imaging agents is also described. In the latter part of the review, a survey of phage-derived in vivo imaging agents is presented, and important recent examples are highlighted. Other imaging applications are also discussed, such as the development of peptide tags for site-specific protein labeling and the use of phage as delivery agents for reporter genes. The review concludes with a discussion of how phage display technology will continue to impact both basic science and clinical applications in the field of molecular imaging.

show abstract

Section: The Process Of Developing Phage-derived In Vivo Molecular Immentioning

confidence: 99%

Phage display and molecular imaging: expanding fields of vision in living subjects

Cochran

2010

Biotechnology and Genetic Engineering Reviews

View full text Add to dashboard Cite

show abstract

“…Examination of the tumor in the same animals or cancer patients with both VEGF-and VEGFR-targeted radiopharmaceuticals or fluorescent probes may give important insight into the expression kinetics of VEGF and VEGFRs during cancer development and cancer therapy. Substantial effort has been devoted to non-invasive imaging of VEGFR expression in cancer over the last two decades and various agents have been developed for SPECT (120)(121)(122), PET (121,123,124), optical imaging, magnetic resonance imaging (MRI) and ultrasound (US). Because of the high affinity to VEGFRs, VEGF121 has emerged as a particularly desirable candidate for tracer development in the literature (125).…”

Section: Targeting Vascular Endothelial Growth Factor Receptor (Vegfr)mentioning

confidence: 99%

VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)

Taurone

Galli²,

Agostinelli

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

“…The 121 , which has a correlation of tumor uptake and VEGFR expression [81]. Furthermore, VEGF DEE , a mutant of VEGF 121 , is labeled by 64 Cu as 64 Cu-DOTA-VEGFDEE, and showed even better VEGFR-2 specificity than the wildtype 64 Cu-DOTA-VEGF 121 [82].…”

Section: Vascular Endothelial Growth Factor Receptor Targeted Imagingmentioning

confidence: 99%

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Zhu

Shim

2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Molecular imaging is one of the fastest growing areas of medical imaging. Positron emission tomography (PET) has been widely used in the clinical management of patients with cancer. Nuclear imaging provides biological information at the cellular, subcellular, and molecular level in living subjects with noninvasive procedures. In particular, PET imaging takes advantage of traditional diagnostic imaging techniques and introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer. 18 F-fluorodeoxyglucose ( 18 F-FDG), the only FDA approved oncological PET tracer, has been widely utilized in cancer diagnosis, staging, restaging, and even monitoring response to therapy; however, 18 F-FDG is not a tumor-specific PET tracer. Over the last decade, many promising tumor-specific PET tracers have been developed and evaluated in preclinical and clinical studies. This review provides an overview of the current non-18 F-FDG PET tracers in oncology that have been developed based on tumor characteristics such as increased metabolism, hyperproliferation, angiogenesis, hypoxia, apoptosis, and tumor-specific antigens and surface receptors.

show abstract

A new PET tracer specific for vascular endothelial growth factor receptor 2

Cited by 103 publications

References 28 publications

Phage display and molecular imaging: expanding fields of vision in living subjects

Phage display and molecular imaging: expanding fields of vision in living subjects

VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Contact Info

Product

Resources

About